Based on the fact that TGFβ is a major mediator of EMT30,31, we hypothesized that crizotinib inhibits TGFβ signaling in EML4-ALK-positive NSCLC cells. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.